IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Gedulin et al.

Appl. No.: 10/518,128

371(c) Filing Date: August 29, 2005

For: Prevention and/or Treatment of

Inflammatory Bowel Disease Using

PYY or Agonists Thereof

Confirmation No.: 7370

Art Unit: 1646

Examiner: Li, Ruixiang

Atty. Docket: 0402US-UTL

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop - Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Statement is being filed along with a Request for Continued Examination (RCE) and response to the final Office Action that was mailed on September 2, 2009, in the above-identified case. Accordingly, this Statement is being filed under the provisions of 37 C.F.R. § 1.97(c)(2), i.e., prior to the mailing of any of a final Action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in the application, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56.

The Commissioner is hereby authorized to charge the associated fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 01-0535.

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. 1.56(b) or that any of the cited references qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

Applicant believes that no other fees are due in connection with the instant case. If Applicants are mistaken, the Commissioner is herewith authorized to charge such fees to Deposit Account No. 01-0535.

Respectfully Submitted

AMYLIN PHARMACEUTICALS, INC.

Dated: December 2, 2009 /Michael D. Ruse, Jr./
Michael D. Ruse, Jr.
Reg. No. 55,900

Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, California 92121 Phone (858) 552-2200 Facsimile (858) 552-1936